Editorial
New Therapy for Merkel Cell Carcinoma (MCC), a Non-Melanoma Skin Cancer
Germame Ajebo* and Zhonglin Hao
Department of Internal Medicine, Georgia Cancer Center, Medical College of Georgia, Augusta University, USA
*Corresponding author: Germame Ajebo, Department of Internal Medicine, Georgia Cancer Center, Medical College of Georgia, Augusta University, USA
Published: 22 Nov, 2017
Cite this article as: Ajebo G, Hao Z. New Therapy for
Merkel Cell Carcinoma (MCC), a Non-
Melanoma Skin Cancer. Clin Oncol.
2017; 2: 1373.
Editorial
PET images of an81 year old man with stage IV Merkel cell carcinoma before (2/24/17)
and after (6/28/17 and 8/29/27) pembrolizumab therapy. Metastases are seen in the right axilla,
bilateral mediastinum, left lung, liver, retroperitoneal nodes, skeleton (SUV 4.7 to 13.6, left).Overall
continued decrease in visceral and skeletal metastatic disease burden with complete metabolic
response of metastatic osseous disease at C1.The new focal uptake in sigmoid diverticulum on
8/28/17is consistent with inflammatory changes from sigmoid diverticulitis.
Merkel cell carcinoma shows similar aggressiveness as small cell lung cancer. Although
chemotherapy with carboplatin and etoposide is often effective (60%response rate), it is often
short-lived and not well tolerated in the elderly [1]. Avelumabhas recently been approved by the US
FDA for stage IV Merkel cell carcinoma. The overall response rate was 33% among the 88 patients
treated after one line of chemotherapy (median follow up 10.4 months) [2]. Pembrolizumab given
to 26 treatment-naïve patients in another phase 2 trial had an overall response rate of 56% with 4
complete responses [3]. Median follow up was 33 weeks (7-53 weeks). The presence or absence of
Merkel cell polyomavirus did not affect the response rate.
References
- Terheyden P, Becker JC. New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. 2017.
- Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016; 17(10): 1374-1385.
- Nghiem PT, Bhatia S, Lipson EJ. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016; 374(26): 2542-2552.